| 产品描述: | TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC50 of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis. |
| 靶点: |
Oxazolidinone |
| 体外研究: |
TBI-223 (80-160 mg/kg,口服,每日两次,7 天) 在 C57BL/6 小鼠 MRSA 菌血症模型中实现 100% 存活率[2]。 TBI-223 (80-160 mg/kg,口服,每日两次,7 天) 在非糖尿病 C57BL/6 小鼠和糖尿病 TallyHo/JngJ 小鼠的 MRSA 皮肤伤口感染模型中显著减少病灶大小[2]。 TBI-223 (80-160 mg/kg,口服,每日两次,7 天) 在 C57BL/6 小鼠的 MRSA 骨科植入物相关感染模型中显著降低体内 BLI 信号、关节组织和植入物 CFU 计数[2]。 |
| 体内研究: |
TBI-223 在 7H9 培养基中对 Mycobacterium tuberculosis 的 MIC50 为 1.50 μg/mL,对 Mycobacterium kansasii 为 2.00 μg/mL,对 MAC 为 8.00 μg/mL,对 MAbC 为 2.00 μg/mL。 |
| 参考文献: |
1. Negatu DA, et al. Side-by-Side Profiling of Oxazolidinones to Estimate the Therapeutic Window against Mycobacterial Infections. Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0165522. 2. Gordon O, et al. The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection. Microbiol Spectr. 2022 Oct 26;10(5):e0245121. |
| 保存条件: |
-20°C |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.737 ml |
13.685 ml |
27.37 ml |
| 5 mM |
0.547 ml |
2.737 ml |
5.474 ml |
| 10 mM |
0.274 ml |
1.369 ml |
2.737 ml |
| 50 mM |
0.055 ml |
0.274 ml |
0.547 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |